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Abstract 
Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with 
increased risk and severity of prostate cancer (PCa). We evaluated whether PSVs in BRCA1/2 
were associated with risk of overall PCa or high grade (Gleason 8+) PCa using an international 
sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with PCa, and 3,388 BRCA1 and 
2,880 BRCA2 male PSV carriers without PCa. PSVs in the 3' region of BRCA2 (c.7914+) were 
significantly associated with elevated risk of PCa compared with reference bin c.1001-c.7913 
(HR=1.78, 95%CI: 1.25-2.52, p=0.001), as well as elevated risk of Gleason 8+ PCa (HR=3.11, 
95%CI: 1.63-5.95, p=0.001). c.756-c.1000 was also associated with elevated PCa risk 
(HR=2.83, 95%CI: 1.71-4.68, p=0.00004) and elevated risk of Gleason 8+ PCa (HR=4.95, 
95%CI: 2.12-11.54, p=0.0002). No genotype-phenotype associations were detected for PSVs in 
BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated 
risk of developing aggressive PCa. 
Statement of Significance 
Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific 
BRCA2 mutation inherited by the at-risk individual 
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Introduction 
Inherited pathogenic sequence variants (PSVs) in DNA repair pathway genes including BRCA1 
and BRCA2 (BRCA1/2) are associated with prostate cancer (PCa) risk and severity(1-15). 
Carriers of BRCA2 PSVs have been reported to have increased levels of serum prostate-
specific antigen (PSA) at diagnosis, increased proportion of high Gleason (7+) tumors, less 
favorable tumor stage, increased rates of nodal and distant metastases, and increased rate of 
recurrence after treatment(2,11-18). BRCA2 PSVs confer lower overall survival and PCa 
specific survival(13-15). Ashkenazi Jewish carriers of BRCA1 PSVs have been reported to have 
elevated rates of Gleason 7+ tumors, higher rates of recurrence, and a five-fold increase in PCa 
death(5,19), although the association of BRCA1 and PCa has not been replicated in all 
studies(20). Distinct tumor PSV, methylation, and expression patterns have been identified in 
BRCA2 compared with non-BRCA2 mutant prostate tumors.  These data suggest that BRCA2 
mutant tumors have features that are more similar to metastatic castrate resistant disease than 
localized PCa(21-23). 
 
Specific genotype-phenotype correlations have been reported(24), including BRCA1/2-
associated breast and ovarian cancers(25-27), APC PSVs and severity of familial adenomatous 
polyposis (FAP)(28,29), and RET PSVs in multiple endocrine neoplasia type 2 (MEN2) and 
Familial Medullary Thyroid Carcinoma(30). There have been suggestions in the literature that 
similar patterns exist for BRCA1 or BRCA2 and PCa. Liede et al.(31) reported that early-onset 
PCa (<age 65 years) was more frequent in men with BRCA2 PSVs outside of the ovarian 
cancer cluster region. More recently, Roed Nielsen et al.(32), using a sample of 37 PCa cases, 
19 of whom had BRCA2 PSVs, identified a region in BRCA2 at c.6373-c.6492 in which PSVs 
were associated with an increased risk of PCa.  
 
We analyzed a large international cohort of 3,453 BRCA1 and 3,051 BRCA2 PSV male carriers 
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to evaluate the distribution of germline PSVs in men diagnosed with PCa and men without prior 
PCa diagnosis. We hypothesized that specific PSVs in BRCA1 or BRCA2 might influence 
development of PCa and be associated with PCa severity. 
 
Materials and Methods 
Study Sample 
The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) is an international 
collaboration of centers on six continents that has collected information about carriers of 
BRCA1/2 PSVs(33). All carriers participated in clinical assessment and/or research studies at a 
participating institution after providing informed consent under protocols approved by local 
institutional review boards. Participants ascertainment date was defined as the time of study 
interview (e.g., enrollment in a research study). Forty-eight centers and multicenter consortia 
(Supplementary Table 1) in 31 countries submitted de-identified data that met the CIMBA 
inclusion criteria as previously described. No races/ethnicities were excluded from this study. 
Self-reported race/ethnicity data were collected across the various centers using either fixed 
categories or open-ended questions. 
 
We analyzed only male carriers with clearly pathogenic BRCA1/2 PSVs that occurred 3’ of 
nucleotide position 1 (A of the ATC translation initiation codon in either BRCA1 and BRCA2. 
This excluded 101 males who had a PSV occurring 5’ translation start site.  Definitions of these 
PSVs are shown in Supplementary Table 2. PSVs were defined using CIMBA criteria as 
follows: (1) PSVs generating a premature termination codon, except those in exon 27 at or after 
codon  3310 of BRCA2; (2) large in-frame deletions that spanned ≥1 exons; and (3) deletions of 
transcription regulatory regions (promoter and/or first exon) expected to cause lack of mutant 
allele expression(33-35).  We also included missense variants considered pathogenic as 
determined by using multifactorial likelihood approaches(35,36). PSVs are described using the 
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Human Genome Variation Society (HGVS) nomenclature (Supplementary Table 2). 
Authors have obtained written informed consent.  
 
Pathogenic Sequence Variant Binning 
To identify segments across the intronic and exonic regions of BRCA1 and BRCA2 associated 
with different PCa risks, we created PSV bins by base pair location within each gene. These 
genomic sequence bins contained all PSVs regardless of category or function, except for large 
genomic rearrangements, which were excluded from this analysis since they may span multiple 
bins. Bins were constructed in two ways. First, we used an algorithm in which each bin 
contained approximately equal numbers of participants (including all cases and controls) with 
bin length defined by distance in base pairs. Thus, bin length for common PSVs (e.g., the 
Icelandic founder PSV c.771_775del) were small compared to bins with a wider range of PSVs. 
We divided the number of PSVs across the span of BRCA1 or BRCA2 into deciles of PSVs 
observed in cases and non-cases (i.e., “decile” bins). Second, we identified putative functional 
domains in BRCA1 or BRCA2 and created bins that captured these domains, as well as bins 
that contained no functional domain. These domains were determined by boundaries reported in 
the pfam database(37). The resulting bin boundaries are presented in Supplementary Table 3 
and shown graphically in Figure 1 for BRCA1 and Figure 2 for BRCA2.  We chose to use these 
two binning methods based on our earlier published research(24) that indicated the inferences 
about mutation risk association differences were similar regardless of the binning approach 
used. After the initial evaluation across all bins (Supplementary Table 3), we further collapsed 
bins that were inferred to have homogeneous PCa, either elevated above or not different from 
the reference bin. 
 
Pathogenic Sequence Variant Type and Function 
In addition to the binning analyses described above, we also considered whether the predicted 
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type and function of heritable BRCA1/2 PSVs in the CIMBA database were associated with 
PCa. The definition of these PSV types and their functions are presented in Supplementary 
Table 2.  PSVs were grouped by type and function as frameshift (FS), nonsense (NS), 
missense (MS), and splice site (SP) (Supplementary Table 2).  PSVs expected to generate 
stable or unstable, or no proteins were designated into previously reported classes 1, 2, or 3(38-
40).  Missense PSVs in BRCA1 were combined into one group that contained PSVs in the 
RING(41,42) and BRCT domains(43-46). We compared PSVs predicted to produce nonsense-
mediated decay (NMD) vs. those that were not. PSVs predicted not to cause NMD were defined 
as those creating a stop codon within 50 nucleotides before or within the last exon(47). 
Premature termination codons comprised all PSVs leading to a truncated open reading frame.  
 
Statistical Methods 
For the first set of analyses assessing all bins across the genes, a different reference group was 
defined for each combination of gene (BRCA1 or BRCA2) and binning scheme (decile or 
functional).  Reference bins were chosen based on analysis of each bin’s association with PCa 
compared with all other bins as a group and found to have the lowest hazard of PCa for each 
gene. The reference bins used in each analysis are shown in Table 1. An exploration of other 
reference bins did not change the inferences of this analysis. 
 
To estimate the relative hazards associated with each bin compared with the reference bin, we 
fitted Cox proportional hazards regression models separately in BRCA1 and BRCA2 PSV 
carriers. The primary outcomes of interest were diagnosis of PCa (vs. no PCa) or Gleason 8+ 
PCa (vs. no PCa) and Gleason <7 (vs. No PCa). Time to event was computed from birth to age 
at PCa diagnosis or age at ascertainment (which ever occurred first). No time or events were 
considered after time of ascertainment. All analyses were adjusted for confounding by race 
(African American vs. any other ethnicity) and birth cohort, defined as those born before or after 
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median birth date of the total sample. We also adjusted all analyses by country of 
ascertainment. We computed the PCa hazard ratio for each defined bin relative to the common 
reference bin. To account for intra-cluster dependence due to multiple individuals from the same 
family, a robust sandwich variance estimate was specified in Cox proportional hazards 
models(48).  
 
Hypothesis tests were judged to be statistically significant based on 2-sided tests with P-value < 
0.05. All P-values were corrected for multiple hypothesis testing within each table of results by 
controlling the false discovery rate (FDR) using the method of Benjamini and Hochberg(49). 
Analyses were conducted in STATA v14, SPSS, or R version 2.7.2 (R Foundation for Statistical 
Computing). 
 
Results 
A total of 3,453 male BRCA1 and 3,051 male BRCA2 PSV carriers were eligible for analysis. 
(see Table 2). The median PCa diagnosis ages were 64 years in both BRCA1 and BRCA2 PSV 
carriers. Among BRCA1/2 PSV carriers, 74% and 81%, respectively, self-reported their race as 
white.  
 
BRCA1 
As shown in Table 1a, there were no statistically significant associations between PSVs in any 
BRCA1 bin and elevated PCa risk. There was also no association of BRCA1 PSVs with 
Gleason 8+ disease with region. 
 
BRCA2  
In BRCA2, we identified a “prostate cancer cluster region” (PCCR) in which PSVs were 
associated with elevated PCa risk. The risk estimates were obtained by considering all PSVs 
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within the region of interest defined by the overlap of bins generated using the “decile” and 
functional binning methods described above. The PCCR included all PSVs 3’ of c.7914 and 
associated with HR=1.78 (95%CI: 1.25-2.52, p=0.001) when compared with PSVs in the 
reference bin c.1001-c.7913 (Table 1b). In addition, we identified a region bounded by c.756 
and c.1000 (Supplementary Table 3 and Figure 2) that was associated with elevated PCa risk 
with HR=2.83 (95% CI: 1.71-4.68, p=4x10-5) compared with PSVs in the reference bin c.1001-
c.7913. This region contains the c.771_775del Icelandic founder PSV, which is the dominant 
PSV in this bin (n=92 of 117 total PSVs in this bin).  Comparison of the risk in carriers of 
c.771_775del to the risk in carriers of PSVs in c.1001-c.7913 gave HR=3.34 (95%CI: 2.01-5.55, 
p=3x10-6). Due to the small number of carriers of other PSVs in this bin (N=25), it was not 
possible to estimate risk of PCa for carriers of the other (non-c.771_775del) PSVs in this bin.  
Risk of PCa among those without a PCCR PSV was not elevated except for carriers of PSVs in 
bin 6 (c.5910-c.6275) (HR=2.83, 95%CI: 1.21-6.58, p=0.016) (Table 2b). Both the PCCR and 
region c.756-c.1000 were contained almost entirely within the previously identified breast cancer 
cluster regions (BCCRs)(24). Collectively, regions in which PSVs were associated with a 
significantly increased risk of PCa development contained the BRCA2 helical plasma domain, 
the oligonucleotide/oligosaccharide-binding domain 1 (OB1), the Tower domain (OB2), and the 
N-terminal PALB2 binding site (Figure 2). Highest risk was associated with PSVs affecting OB1 
and OB2 (Figure 2).  
 
Risk of high-grade PCa (Gleason 8+) was even more strongly associated with PSVs in the 
PCCR (HR=3.11, 95% CI: 1.63-5.95, p=0.001; Table 1c).  A similar association was also 
observed for PSVs in the region containing the Icelandic founder PSV, c.771_775_del 
(HR=4.95, 95% CI: 2.12-11.54, p=2x10-4), and the c.771_775del PSV itself (HR=5.66, 95% CI: 
2.43-13.22, p=6x10-5) Together, these regions were associated with increased Gleason 8+ PCa 
risk (HR=3.80, 95% CI: 2.10-6.89, p=1x10-5). Risk of Gleason <7 PCa was elevated for carriers 
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of c.771_775del (HR=3.29, 95%CI: 1.38-7.83, p=0.007), but not elevated for those with PSVs in 
the PCCR (HR=1.56, 95%CI: 0.88-2.78, p=0.130; Table 1c).   
 
To ensure that the inferred effects were not due to the common Jewish founder PSV c.5946del 
that was included in the reference bin, we repeated calculations after excluding carriers these 
PSVs from the reference bin. After excluding these PSV carriers from the reference bin, the 
association with PSVs in the bin containing the c.771_775del and in the PCCR remained 
statistically significant (HR=3.03, 95%CI: 1.83-5.04, p=2x10-5 and HR=1.89, 95%CI: 1.34-2.66, 
p=3x10-4, respectively). Similarly, we repeated the analysis including only self-identified 
Caucasians. In part because of the small number of non-Caucasians in the study, the point 
estimates did not change to the second decimal place compared with the total sample that 
included non-Caucasians. Finally, we corrected for correlation due to the presence of multiple 
individuals in a family.  With and without this correction, no change in the inferences were 
observed. 
 
Pathogenic Sequence Variant Type and Function 
In addition to seeking for regional variation in PCa risk associated with PSVs across BRCA1/2, 
we also evaluated potential genotype-phenotype correlations by PSV type or function (Table 3). 
No PSV groups defined by type or function were significantly associated with prostate cancer for 
either BRCA1 or BRCA2. 
 
Discussion 
Using a multinational data resource of ~6,500 men carrying a BRCA1/2 PSV, we identified 2 
regions in BRCA2 (c.756-c 1000 and c.7914+) that were associated with increased risk of PCa 
diagnosis and of Gleason 8+ PCa. These data suggest that PSV-specific PCA-risks exist for 
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BRCA2 PSV carriers.  This observation is consistent with earlier studies reporting a PSV-
specific increase in PCa risk among BRCA1/2 PSV carriers(31,32). However, most studies that 
have made these observations have estimated the prevalence of BRCA1/2 mutations in PCa 
cases.  Few studies have evaluated PCa incidence in mutation BRCA1/2 carriers.  Roed 
Nielsen et al. (32) reported an elevated PCa relative risk in BRCA2 mutation carriers whose 
mutations fell in c.6373-c.6492 with a relative risk  of 3.7 for mutations within this region 
compared with mutations outside this region. This elevated relative risk was not observed in the 
larger current analysis, which included the carriers reported by Roed Nielsen. We also 
demonstrated a remarkable similarity between PSVs conferring increased PCa risk and those 
associated with increased breast cancer risk in female BRCA2 PSV carriers(24). 
 
BRCA2 is among the few known clinically relevant loci, in which many deleterious variants 
cause a highly penetrant PCa predisposition(50). Our work addressed the hypothesis that 
germline PSVs in BRCA1/2 that influence development of overall PCa and PCa severity 
demonstrate nonrandom distribution by location and/or function of the gene. Since PCa patients 
with Gleason 8+ disease are far more likely than men with Gleason <8 PCa to have unfavorable 
clinical outcome(2,11-18), the observation that PCCR PSVs are associated with elevated 
Gleason score suggests that PCCR PSVs may be associated with poorer prognosis than other 
BRCA2 PSVs.  However, this needs to be investigated in future studies. We observe an 
elevated risk of both Gleason 8+ and Gleason <7 cancers, although the magnitude of 
association for Gleason 8+ is higher than that for Gleason <7. Thus, it is possible that the PCCR 
reported here is associated with PCa in general, and not only with high grade PCa.  This 
observation requires additional research to confirm. Additionally, knowledge of the importance 
of DNA damage repair suggests that the mechanism of prostate carcinogenesis is broadly 
modified by BRCA2-related pathways(23). The IMPACT trial reported that PSA screening may 
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be more informative in detecting PCa in BRCA2 PSV carriers compared with non-carriers(51). 
Additional research is needed to evaluate whether the PCCR PSVs reported here also influence 
the results of different management strategies.  
 
In addition to its co-location with a previously-identified breast cancer cluster region(24), PSVs 
in the PCCR (3’ of c.7914) are focused within two of the principal DNA binding domains of the 
OB1 (i.e., oligonucleotide/oligosaccharide-binding domain 1; amino acids 2670 - 2796) and OB2 
(i.e., Tower ssDNA and dsDNA binding domain 2; amino acids 2831 - 2872). However, the 
present data set does not allow us to understand the mechanism that might explain why BRCA2 
PCCR PSVs are associated with elevated PCa risks. Additional mechanistic research will be 
required to elucidate the biological basis for risk heterogeneity implied by the present results. 
 
The most common PSV in the c.756-c.1000 region was the Icelandic and Finnish founder PSV, 
c.771_775del, which has long been known as a PCa predisposition PSV(52-54) and is 
associated with a rapid progression to fatal PCa(10). Thus, our results regarding the association 
of this founder PSV with PCa severity are consistent with this prior report. We were not able to 
infer if c.756-c.1000 is a second PCCR region, or if the observed effect is due solely to 
c.771_775del. We returned to the original data from participants with this PSV to identify any 
potential bias in ascertainment that may have influenced this result. Based on original records 
from the Icelandic clinics from which these men were ascertained, no individual was ascertained 
based on genetic testing of prostate cancer. The carriers of this PSV were identified through 
family studies of breast cancer, mainly by screening unselected breast cancer patients and 
then, if mutation positive, by screening their close relatives. There was no ascertainment 
preference for prostate cancer cases (Aðalgeir Arason, Personal communication).  
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Our present results complement the growing body of knowledge that cancer susceptibility PSVs 
demonstrate clinically relevant genotype-phenotype relationships. PSV location within APC is 
associated with polyposis severity and prevalence of extracolonic features, such as desmoid 
fibromas(55). Similarly, genotype-phenotype relationships have been reported for (missense) 
PSVs in RET in multiple endocrine neoplasia type 2 (MEN2) and Familial Medullary Thyroid 
Carcinoma(30). These findings have shaped the Neuroendocrine Tumor Society consensus 
guidelines, which now suggest thyroidectomy before age five years for individuals with PSVs 
within these high-risk regions, providing insight into the structure and function of cancer 
susceptibility PSVs in these genes and guiding clinical risk assessment and management. 
Despite evidence of genotype-phenotype relationships at multiple loci, the characteristics and 
mechanistic influences on cancer risk are likely quite different for PVSs in APC, RET, BRCA1/2, 
and others. 
 
In contrast to prior work that evaluated prevalence of PSVs in BRCA1/2 in various PCa case 
series, we have leveraged a large, international multicenter consortium study of BRCA1/2 PSV 
carriers, irrespective of PCa status. However, our analysis has some limitations.  The CIMBA 
study uses a non-standardized recruitment strategy from multiple referral centers.  Thus, our 
data may not represent either the full spectrum of PCa patients or BRCA1/2 PSV carriers in the 
general population.  Similarly, we were not able to assess issues of survival bias in our data that 
may be related to cancer screening or treatment.  
 
While the present study identifies potentially interesting PSV-specific PCa associations, there 
are limitations in the data and analysis that require future validation. We used two binning 
approaches to identify relevant regions of BRCA1/2 that could have different risk or penetrance 
effects on PCa based on our earlier research that undertook a similar analysis for breast and 
ovarian cancer(24). In that analysis, we determined that the combination of these two 
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approaches were complementary and identified similar regions of interest. While this approach 
points toward genomic regions that may confer different PCa risks, a full understanding of the 
causes of the effects we report will require experimental and mechanistic studies to further 
define the boundaries of the relevant domains and to understand the underlying mechanisms 
that lead to the observations reported here. In addition, the choice of the reference bin in our 
analysis will affect estimates of the hazard ratios reported here. Thus, the present report 
focuses on the identification of genomic regions that may confer elevated PCa risks in BRCA2 
mutation carriers, and the hazard ratio estimates presented here should be interpreted with 
caution and not used for clinical risk estimation purposes. 
 
Studies in female PSV carriers using a study design similar to that used here applied analytical 
corrections to account for the possibility that affected individuals (particularly those affected at 
younger ages) are more likely to be sampled than unaffected individuals. Unlike prior breast and 
ovarian cancer studies in BRCA1/2 mutation carriers, the present sample did not ascertain 
specific PCa cases (e.g., those diagnosed at an early age).  Our median age at diagnosis is 64 
years, which is similar to that reported in other non-BRCA1/2 populations. Our case sample is 
substantially older than PCa cases ascertained for BRCA1/2 screening studies, which tend to 
have a large proportion of cases diagnosed before age 55 (56). Thus, while there is limited 
evidence that ascertainment of cases conferred a major bias to the present results, future 
research is required to determine the extent of bias in our relative risk estimates arising from 
these issues.  
 
Finally, pathology review of prostate tumors was neither centralized or available for all cases.  A 
relatively large proportion of Gleason score and tumor stage data were also missing from the 
present sample, since many cases were based on self-report only. Cases with missing tumor 
Research. 
on November 15, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2019; DOI: 10.1158/0008-5472.CAN-19-1840 
 34 
stage and grade were excluded from those analyses, so any differential reporting of tumor traits 
could have caused bias in those results.   
 
The present study indicates that personalized PCa risk assessment may be a future option, as 
well as individualized clinical management based on the specific BRCA2 PSV status. Additional 
research is required to fully understand the implication of carrying specific BRCA2 PSVs. 
Further characterization of the relationship between these PSVs and various cancer outcomes 
might help direct the future use of DNA repair-directed treatments and radiation therapy in men 
carrying these PSVs.  
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Table 1: Association Analyses of Prostate Cancer by bin for BRCA1 and BRCA2 PSVs 
 
BRCA1 – All Prostate Cancer 
 
    
 
Grouping Bin Nucleotide Range PC+ PC- HR 95% CI p-value 
BRCA1 Decile 
1 <c.81 11 339 1.06 0.36-3.13 0.917 
2 c.82-c.302 5 325 REF 
  
3 c.303 – c.1504 4 331 0.82 0.23-2.92 0.761 
4 c.1505 – c.2475 8 431 1.09 0.34-3.43 0.888 
5 c.2476 – c.3319 3 274 0.33 0.15-2.60 0.526 
6 c.3320 – c.3710 5 308 1.32 0.36-4.89 0.677 
7 c.3711 – c.4065 9 318 1.96 0.65-5.86 0.230 
8 c.4066 – c.5030 1 333 0.16 0.02-1.27 0.084 
9 c.5031 – c.5266 13 425 1.68 0.58-4.84 0.339 
10 c.5267+ 2 231 0.49 0.10-2.49 0.389 
BRCA1 
Functional 
1 <c.181 13 515 0.72 0.34-1.53 0.396 
2 c.182-c.1287 6 433 0.83 0.32-2.20 0.713 
3 c.1288-c.2475 9 478 0.93 0.37-2.36 0.887 
4 c.2476-c.3607 5 487 0.58 0.19-1.75 0.333 
5 c.3608-c.4183 12 462 1.19 0.54-2.64 0.671 
6 c.4184-c.5194 5 485 0.38 0.12-1.25 0.112 
7 c.5195+ 11 455 REF 
  
        
 
BRCA2 – All Prostate Cancer 
 
Grouping Bin Nucleotide Range PC+ PC- HR 95% CI p-value 
Decile 
1 <c.755 12 296 1.71 0.66-4.46 0.268 
2 c.756-c.1813 25 277 3.38 1.24-9.19 0.017 
3 c.1814-c.3530 6 293 REF 
  
4 c.3531-c.4965 13 296 2.00 0.69-5.76 0.202 
5 c.4966-c.5909 13 307 2.14 0.66-7.00 0.207 
6 c.5910-c.6275 30 334 2.83 1.21-6.58 0.016 
7 c.6276-c.7007 12 214 2.69 0.89-8.13 0.079 
8 c.7008-c.7913 10 285 2.12 0.60-7.42 0.240 
9 c.7914-c.8953 26 281 3.32 1.28-8.65 0.014 
10 c.8954+ 23 274 4.26 1.60-11.37 0.004 
Functional 
1 <c.1000 27 398 1.39 0.74-2.64 0.307 
2 c.1001-c.3005 14 397 0.80 0.39-1.63 0.535 
3 c.3006-c.5172 16 408 REF 
  
4 c.5173-c.6255 32 498 1.01 0.53-1.93 0.967 
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Grouping Bin Nucleotide Range PC+ PC- HR 95% CI p-value 
5 c.6256-c.7436 24 400 1.44 0.74-2.82 0.286 
6 c.7437-c.8616 28 390 1.68 0.91-3.13 0.100 
7 c.8617+ 29 366 1.64 0.90-3.01 0.106 
Elevated vs.  
No Elevated 
PCa Risk  
1 <c.755 12 296 0.73 0.40-1.31 0.288 
  2* c.756-c.1000 15 102 2.83 1.71-4.68 4x10-5 
3 c.1001-c.7913 94 1904 REF 
  
PCCR c.7914+ 49 555 1.78 1.25-2.52 0.001 
Elevated vs. 
No Elevated 
PCa Risk 
No 
Elevated 
PCa Risk 
 
<c.755, c.1001-
c.7913 
106 2,200 REF 
  
Elevated 
PCa Risk 
c.756-c.1000, 
c.7914+ 
65 657 2.02 1.48-2.77 9x10-6 
 
BRCA2 –Prostate Cancer by Gleason Grade 
 
Gleason 8+ Bin Nucleotide Range PC+ PC- HR 95% CI p-value 
 
Bins with Elevated 
Risk 
1 <c.755 2 299 0.53 0.12-2.32 0.399 
2 c.756-c.1000 6 108 4.95 2.12-11.54 2x10-4 
3 c.1001-c.7913 19 1940 REF 
  
PCCR c.7914+ 18 572 3.11 1.63-5.95 0.001 
Bins with Elevated 
Risk 
No 
Elevated 
PCa Risk 
 
<c.755,  
c.1001-c.7913 
21 2239 REF 
  
Elevated  
PCa Risk 
 
c.756-c.1000, 
c.7914+ 
 
24 
 
680 
 
3.80 
 
2.10-6.89 
 
1x10-5 
         
Gleason <7        
 
Bins with Elevated 
Risk 
1 <c.755 3 298 0.47 0.14-1.57 0.221 
  2* c.756-c.1000 6 108 3.29 1.38-7.83 0.007 
3 c.1001-c.7913 36 1923 REF 
  
PCCR c.7914+ 17 573 1.56 0.88-2.78 0.130 
Bins with Elevated 
Risk 
No 
Elevated 
PCa Risk 
 
<c.755,  
c.1001-c.7913 
39 2221 REF 
  
Elevated 
PCa Risk 
c.756-c.1000, 
c.7914+ 
23 681 1.89 1.14-3.14 0.014 
*Bin containing Icelandic Founder PSV c.771_775del 
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Table 2: Characteristics of Study Participants 
 
  
 Carriers of PSV  
in BRCA1  
 Carriers of PSV 
in BRCA2 
 
 
Total 
 N  
3,453 
% 
 N 
3,051 
% 
 
Region 
Asia  76 2.2   90 2.9 
Australia  386 11.2   292 9.6 
Europe  2,287 66.2   2,165 71.0  
North America  662 19.2   497 16.3  
South America  42 1.2   7 0.2  
Self-Identified 
Race/Ethnicity 
Caucasian  2,557 74.1   2,455 80.5  
African 
American 
 
20 0.6  
 
14 0.5  
Asian  76 2.2   101 3.3  
Hispanic  54 1.6   16 0.5  
Jewish  124 3.6   94 3.1  
Other  45 1.3   10 0.3  
Unknown  575 16.7   358 11.7  
Ascertainment 
Clinic-based   3,352 97.1   2,969 97.3  
Population-
based 
 
101 2.9  
 
82 2.7  
PCa 
Yes  65 1.9  171 5.5 
No   3,388 98.1  2,880 94.4 
Gleason 
Score 
<6 
 
16 24.6 
 
32 18.7 
 7  9 13.8  30 17.5 
 8  3 4.6  16 3.1 
 9  7 10.8  26 15.2 
  10  0 0.0   5 2.9 
 Missing  30 46.2  62 36.2 
M Stage 
M0  18 27.7  33 19.3 
M1  2 3.1  14 8.2 
MX  8 12.3  28 16.4 
 Missing  37 56.9  96 56.1 
Other Cancer 
Diagnosis 
Yes 
 
332 9.6 
 
657 21.5 
No  3,121 90.4  2,389 78.5 
  
N Median Range N Median Range 
Age at Ascertainment (yrs) 3,453 50 18-91 3,051 51 18-101 
Time to PCa or Censoring (yrs) 3,453 50 18-91 3,051 54 18-101 
Age at PCa Diagnosis (yrs) 65 64 30-85 171 64 29-87 
Age at Other Cancer Diagnosis 
(yrs) 
332 59 19-88 657 60 21-88 
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Table 3: Association of Pathogenic Sequence Variant (PSV) Type or Function with risk of prostate cancer. Hazard Ratios 
(HRs) represent the comparison of PSVs with a certain type or function designation vs. all other PSVs. HRs are adjusted 
for year of birth cohort, race, and country of ascertainment. 
 
   BRCA1 mutation carriers BRCA2 mutation carriers 
PSV type N PCa HR (95% CI) p-value N PCa HR (95% CI) p-value 
Premature 
Truncating 
Codon 
2,720 54 (2.0%) 1.04 (0.47-2.28) 0.931 2,699 151 (5.6%) 0.90 (0.40-2.04) 0.805 
Nonsense-
Mediated 
Decay 
1,996 31 (1.6%) 0.65 (0.38-1.11) 0.117 2,692 150 (5.6%) 0.86 (0.41-1.82) 0.698 
Class 1 2,489 48 (1.9%) 0.80 (0.44-1.47) 0.474 2,712 151 (5.6%) 0.81 (0.37-1.78) 0.596 
Deletion 279 5 (1.8%) 0.79 (0.32-1.95) 0.606 57 5 (8.8) 1.25 (0.51-3.08) 0.469 
Frameshift 1,845 43 (2.3%) 1.66 (0.99-2.77) 0.055 2,040 115 (5.6%) 1.01 (0.74-1.41) 0.910 
Insertion 61 0 * * 21 0  * * 
Missense 283 3 (1.1%) 0.66 (0.21-2.11) 0.488 60 4 (7%) 1.08 (0.37-3.17) 0.886 
Nonsense 679 9 (1.3%) 0.68 (0.34-1.36) 0.271 591 32 (5.4%) 0.94 (0.64-1.39) 0.740 
Splicing 306 5 (1.6%) 0.94 (0.39-2.30) 0.896 282 15 (5.3%) 1.00 (0.57-1.76) 0.994 
*Could not be estimated. 
 
Research. 
on November 15, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2019; DOI: 10.1158/0008-5472.CAN-19-1840 
 52 
Figure Legends 
Figure 1: BRCA1 Pathogenic Sequence Variant Distribution  
The x-axis displays the amino acid sequence of the BRCA1 gene. The violet markers 
indicate the position of PSVs found in the BRCA1 PSV carriers. The vertical position of 
the markers on the y-axis indicates the frequency of the PSV found in the cohort. 
Additionally, the blue and tan bars with corresponding axis markers delineate the bins of 
the BRCA1 PSVs that were created using the “decile” binning strategy and the 
“functional” binning strategy. Orange and light blue bars indicate the position of breast 
and ovarian cancer cluster regions, respectively, as identified in the CIMBA breast 
cancer cohort (Rebbeck et al. JAMA 2015). Lastly, known functional domains within the 
BRCA1 gene are highlighted. 
A. Distribution of total BRCA1 PSVs in carriers, B. Distribution of BRCA1 PSVs in 
carriers who did not develop prostate cancer, C. Distribution of BRCA1 PSVs in carriers 
who developed prostate cancer. 
 
Figure 2. BRCA2 Pathogenic Sequence Variant Distribution 
The x-axis displays the amino acid sequence of the BRCA2 gene. The violet markers 
indicate the position of PSVs found in the BRCA2 PSV carriers. The vertical position of 
the markers on the y-axis indicates the frequency of the PSV found in the cohort. 
Additionally, the blue and tan bars with corresponding axis markers delineate the bins of 
the BRCA2 PSVs that were created using the “decile” binning strategy and the 
“functional” binning strategy. Orange and light blue bars indicate the position of breast 
and ovarian cancer cluster regions, respectively, as identified in the CIMBA breast 
cancer cohort (Rebbeck et al. JAMA 2015). Lastly, known functional domains within the 
BRCA2 gene are highlighted. 
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A. Distribution of total BRCA2 PSVs in carriers, B. Distribution of BRCA2 PSVs in 
carriers who did not develop prostate cancer, C. Distribution of BRCA2 PSVs in carriers 
who developed prostate cancer. 
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